Skip to main content
Premium Trial:

Request an Annual Quote

Immunai Closes $215M Series B Round

NEW YORK – Immune profiling firm Immunai said Wednesday it has closed a $215 million Series B funding round.

The New York City-based company said it plans to use the funds to expand the use of its AMICA (Annotated Multiomic Immune Cell Atlas) resource, a collection of clinically annotated single-cell immune data, in drug target identification and drug development.

The Series B round was led by Koch Disruptive Technologies with participation from investors including Talos VC, 8VC, Alexandria Venture Investments, Piedmont, and Icon. With the round, Immunai has now raised $295 million in total funding since its launch.

The company said it has tripled in size in the last year to more than 120 employees and has established more than 30 partnerships with pharma companies and academic institutions.

“We have made great progress towards our core mission of understanding the immune system, which we believe is essential to finding the answers to human health and disease,” Noam Solomon, CEO and cofounder of Immunai, said in a statement. "Unlocking the immune system will accelerate the evaluation and development of novel immune medicines. Our approach is to combine best-in-class single-cell genomic methods and artificial intelligence with a deep understanding of immunology."

“Immunai is leaving no stone unturned in understanding and developing technology to map the immune system — critical scientific work that will give us greater knowledge to treat diseases and improve patient outcomes,” said Eli Groner, managing director at Koch Disruptive Technologies. "We invested in Immunai because we recognize that understanding the immune system and its incredible complexity is key for the future of medicine."